Please assess the completion status of the following clinical trial:

Trial Title: A Study of Tarceva (Erlotinib) Following Platinum-Based Chemotherapy in Patients With Advanced, Recurrent, or Metastatic Non-Small Cell Lung Cancer (NSCLC)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* adult patients \>=18 years of age;~* histologically documented, locally advanced , recurrent or metastatic NSCLC;~* measurable disease;~* no disease progression after 4 cycles of platinum-based chemotherapy.~Exclusion Criteria:~* unstable systemic disease;~* any other malignancies in the last 5 years.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Erlotinib (Type: EXPERIMENTAL): Participants received erlotinib, 150 milligrams (mg), orally (PO), daily from randomization until progressive disease (PD), death, or unacceptable toxicity.
- Placebo (Type: PLACEBO_COMPARATOR): Participants received a placebo, PO, daily, from randomization until PD, death, or unacceptable toxicity.

Based on this trial design, predict the completion outcome and termination type (if applicable).